Development of Group B Coxsackievirus as an Oncolytic Virus: Opportunities and Challenges
Oncolytic viruses have emerged as a promising strategy for cancer therapy due to their dual ability to selectively infect and lyse tumor cells and to induce systemic anti-tumor immunity. Among various candidate viruses, coxsackievirus group B (CVBs) have attracted increasing attention in recent year...
Main Authors: | Huitao Liu, Honglin Luo |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-06-01
|
Series: | Viruses |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4915/13/6/1082 |
Similar Items
-
Coxsackievirus B3—Its Potential as an Oncolytic Virus
by: Anja Geisler, et al.
Published: (2021-04-01) -
Enhanced genomic stability of new miRNA-regulated oncolytic coxsackievirus B3
by: Huitao Liu, et al.
Published: (2022-12-01) -
Oncolytic activity of a coxsackievirus B3 strain in patient-derived cervical squamous cell carcinoma organoids and synergistic effect with paclitaxel
by: Yanzhen Lin, et al.
Published: (2024-10-01) -
Immunological Effects of Oncolytic Coxsackievirus A21 on the Mouse Model of Colorectal Cancer
by: Reza Karbalaee, et al.
Published: (2022-08-01) -
Application Route and Immune Status of the Host Determine Safety and Oncolytic Activity of Oncolytic Coxsackievirus B3 Variant PD-H
by: Ahmet Hazini, et al.
Published: (2021-09-01)